Multiple myeloma remains a challenging plasma cell malignancy despite recent therapeutic advancements. Recent studies highlight how epigenetic crosstalk in myeloma significantly drives disease onset, progression, and treatment resistance. This intricate interplay between DNA methylation, histone modifications, and non-coding RNAs reshapes the bone marrow niche to favor tumor survival. Consequently, understanding these mechanisms is essential for developing novel precision therapies for patients.

DNA Methylation and Gene Silencing

DNA methylation abnormalities feature prominently in the early and late stages of myeloma. Specifically, locus-specific hypermethylation often silences critical tumor suppressor genes. This process disrupts vital pathways such as Wnt/\u03b2-catenin, JAK/STAT, and apoptotic signaling. Conversely, global hypomethylation contributes to genomic instability and disease progression. Notably, these changes create a unique epigenetic landscape that fosters clonal expansion and survival.

Histone Modifiers as Therapeutic Targets

Histone methyltransferases and deacetylases play central roles in chromatin remodeling. For instance, enzymes such as EZH2 and MMSET frequently exhibit altered activity in myeloma cells. This dysregulation promotes a drug-resistant phenotype and enhances malignant cell survival. Fortunately, inhibitors targeting these modifiers show significant promise in clinical trials. Researchers are currently focusing on overcoming therapeutic resistance by combining these agents with standard-of-care treatments.

Future Directions: Targeting Epigenetic Crosstalk in Myeloma

Investigators are actively exploring long non-coding RNAs, including MALAT1 and MIAT1, as potential biomarkers and therapeutic targets. These molecules further regulate the epigenetic state and contribute to therapeutic failure. Therefore, multi-targeted approaches that address multiple epigenetic layers may improve patient outcomes significantly. Integrating epigenetic inhibitors into existing protocols represents a major frontier in modern hematology.

FAQs

What is the role of EZH2 in multiple myeloma?

EZH2 is a histone methyltransferase that often shows overexpression in myeloma. It promotes chromatin remodeling, which supports myeloma cell survival and contributes to drug resistance.

How do lncRNAs affect drug resistance in MM?

Dysregulated long non-coding RNAs like MALAT1 interact with epigenetic modifiers. This interaction helps maintain genomic instability and allows cancer cells to bypass the effects of conventional therapies.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Alipoor SD et al. Deciphering epigenetic crosstalk in multiple myeloma pathogenesis and treatment. Clin Epigenetics. 2026 Apr 09. doi: 10.1186/s13148-026-02109-w. PMID: 41957661.

2. Kumar S, Kats LM, Gruber E. Epigenetic reprogramming in multiple myeloma-Challenges and opportunities. Int J Cancer. 2026 Jan 15;158(2):423-432. doi: 10.1002/ijc.35426.

3. Alzrigat M, Jernberg-Wiklund H. Epigenetics in multiple myeloma: From mechanisms to therapy. Semin Cancer Biol. 2018 Aug;51:101-115. doi: 10.1016/j.semcancer.2017.09.007.